Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor-Reference-Cited by-同舟云学术

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor

Published:2020-11-17 Issue:6 Volume:8 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol. Res. Perspect.

Author:

Joshi Samit R.¹^ORCID,Fernando Disala²,Igwe Stephanie²,McKenzie Litza³,Krishnatry Anu S.⁴,Halliday Fiona⁵,Zhan Joyce⁴,Greene Thomas J.⁴,Xu Jianfeng⁴,Ferron‐Brady Geraldine⁴,Lataillade Max¹,Min Sherene⁶

Affiliation:

1. ViiV Healthcare Branford CT USA

2. GlaxoSmithKline Clinical Unit Cambridge Cambridge UK

3. Quotient Sciences Nottingham UK

4. GlaxoSmithKline Upper Providence PA USA

5. GlaxoSmithKline Stockley Park UK

6. ViiV Healthcare Research Triangle Park NC USA

Funder

ViiV Healthcare

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.671

Reference7 articles.

1. Virus maturation as a new HIV-1 therapeutic target

2. DeJesusE HarwardS JewellRC et al.A phase IIa study of novel maturation inhibitor GSK2838232 in HIV patients. Slides presented at: Conference on Retroviruses and Opportunistic Infections; March 4–7 2019; Seattle WA.

3. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS‐955176) plus tenofovir/emtricitabine once daily in treatment‐naive HIV‐1‐infected adults: week 24 primary analysis from a randomized phase IIb trial;Morales‐Ramirez J;PLoS One,2018

4. Can the further clinical development of bevirimat be justified?;Wainberg MA;AIDS,2010

5. Pharmacological intervention of HIV-1 maturation

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review;Contraception;2024-10

2. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved;Bioorganic & Medicinal Chemistry;2024-09

3. Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants;Pharmacology Research & Perspectives;2023-11-14

4. Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir;Nature Communications;2023-10-23

5. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults;British Journal of Clinical Pharmacology;2023-09-20